Interval between last neoadjuvant chemotherapy and surgery and between surgery and first adjuvant chemotherapy in ovarian cancer patients.

Authors

null

Alexandre Andre B. A. Da Costa

A.C. Camargo Cancer Center, São Paulo, Brazil

Alexandre Andre B. A. Da Costa , Adriana Regina Goncalves Ribeiro , Henrique Mantoan , Carlos Stecca , Elizabeth Santana dos Santos , Joao Paulo Lima , Audrey Oliveira , Deborah Porto Cotrim , Larissa Von Grapp , Victor Aurelio Ramos Sousa , Joyce Maria L. Maia , Andrea Paiva Guimaraes , Glauco Baiocchi

Organizations

A.C. Camargo Cancer Center, São Paulo, Brazil, A.C.Camargo Cancer Center, São Paulo, Brazil, Hospital Sírio Libanês, São Paulo, Brazil, Oncologia Clínica, Hospital A. C. Camargo, São Paulo, Brazil

Research Funding

Other

Background: Neoadjuvant chemotherapy (NCT) is an option to treat ovarian cancer patients with bulky peritoneal disease who are not good candidates to complete primary debulking surgery. The best timing of NCT pause before surgery and restart after surgery is not clearly established. A recent paper suggested a longer interval between last NCT and first adjuvant chemotherapy (ACT) could have a negative prognostic impact. In this paper we evaluated the optimal timing between last NCT and surgery and between surgery and first ACT. Methods: We retrospectively evaluated ovarian cancer patients treated with NCT and debulking surgery at A.C.Camargo Cancer Center – Brazil from 2007 to 2017. At our institution, primary debulking surgery is the standard care, and patients are treated with NCT if there is a high risk for incomplete debulking in primary surgery or the patient have a poor performance status. Interval between last NCT and surgery and between surgery and first ACT were calculated and other clinical characteristics and outcomes collected. We used a cut-off finder method that optimizes the cut-off according to the statistical significance of the hazard ratio for overall survival (OS). Results: There were 122 patients treated with NCT and with available clinical data. Median age was 62.2 years old, 87.7% of patients had high grade serous carcinoma, 6.6% had ECOG performance status of 2 or worse, 78.8% had FIGO stage IIIC disease and 19.7% had FIGO stage IV disease. Interval debulking surgery with residual disease smaller than 1cm was achieved in 73.0%. Median interval between last NCT and surgery was 55.0 days and between surgery and first ACT was 49 days. With a median follow-up of 46.6 months median OS was 48.3 months. Interval between last NCT and surgery longer than 55 to 60 days had a negative impact on survival, and interval between surgery and first ACT between 50 and 60 day had a negative impact on survival. Other cut-off values for this interval resulted in no significant impact on OS. Number of NCT cycles had no impact on OS. Conclusions: Interval between NCT and surgery and between surgery and ACT should be no longer than 60 days.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Citation

J Clin Oncol 36, 2018 (suppl; abstr e17558)

DOI

10.1200/JCO.2018.36.15_suppl.e17558

Abstract #

e17558

Abstract Disclosures